Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Life Span After Alzheimer's Diagnosis: What Factors Matter MostLots of Napping Could Raise a Senior's Odds for Alzheimer'sIs It 'Pre-Alzheimer's' or Normal Aging? Poll Finds Many Americans UnclearMore Evidence That Education May Protect Against DementiaAHA News: These Three Risk Factors May Have the Biggest Impact on Dementia CasesAHA News: Traumatic Brain Injury May Raise Veterans' Long-Term Stroke RiskMore Years Playing Hockey, Higher Odds for CTE Linked to Head InjuryPandemic Caused Rise in Deaths of Alzheimer's PatientsStaying Fit May Keep Alzheimer's at BayConcussion's Impact on Memory, Thinking May Linger More Than a YearBrain Injuries May Be Driving Higher Death Rate for U.S. VeteransAHA News: Statistics Report Offers Snapshot of the Nation's Brain Health – And a Guide to Protecting ItKeeping Weight Stable Could Help Save Your BrainMedicare Proposes to Only Cover Alzheimer's Drug Aduhelm for Use in Clinical TrialsAduhelm: Will Medicare Cover the Controversial Alzheimer's Drug?More U.S. Seniors, Especially Women, Are Retaining Healthy Brains: StudyMaker Cuts Price of Controversial New Alzheimer's Drug in HalfCould Viagra Help Prevent Alzheimer's?Lifetime Spent With Epilepsy Ages the Brain, Study Finds'Mild Cognitive Impairment' in Older Age Often Disappears, Study FindsMore Years Playing Football, More Brain Lesions on MRI: StudyReminder Apps on Smartphones May Help in Early DementiaNeurologists' Group Issues Guidance to Families on Controversial Alzheimer's DrugTrial Begins of Nasal Vaccine for Alzheimer's DiseaseAlzheimer's Diagnosis May Come With Big Cost to Social LifeCould Estrogen Help Shield Women's Brains From Alzheimer's?Purrfect Pal: Robotic Cats May Help People With DementiaRight Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Most Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyAHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check
Links
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Most Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: Study

HealthDay News
by Steven Reinberg
Updated: Sep 14th 2021

new article illustration

TUESDAY, Sept. 14, 2021 (HealthDay News) -- U.S. approval of the Alzheimer's drug Aduhelm is already mired in controversy. Now a new study finds that most Alzheimer's patients could not have taken part in clinical trials that led to the green light.

In June, the U.S. Food and Drug Administration gave accelerated approval to Aduhelm (aducanumab) for treating patients with mild cognitive impairment or mild dementia from Alzheimer's disease.

The decision quickly came under fire because of the Biogen drug's high price -- $56,000 a year -- and questions about possible collaboration between regulators and the drug's maker.

Now, this new study points to other limitations.

The phase 3 trials of the drug showed an increased risk of certain adverse vascular events. Although the trials excluded elderly patients, those with certain chronic diseases and those using blood thinners, the FDA approved use of the drug in these patient populations without noting any precautions.

"Our findings are concerning given the broad FDA labeling for aducanumab," said researcher Dr. Timothy Anderson, an assistant professor of medicine at Beth Israel Lahey Health in Boston.

"The public conversation on aducanumab has focused on limited benefit and high costs. It is equally important to consider that the majority of patients with Alzheimer's disease are likely to face higher risks of adverse events than the patients studied in the trials," Anderson said in a health system news release.

For the study, the researchers looked at Medicare claims among 27 million patients with either cognitive (mental) impairment, Alzheimer's disease or Alzheimer's disease-related disorders.

They found that most of these patients had one or more conditions that would have banned them from the aducanumab clinical trials, including cardiovascular disease, stroke, use of blood thinners, or being over 85.

For example, data showed that about 9 out of 10 patients with Alzheimer's disease-related dementia or Alzheimer's disease itself had at least one factor that would have excluded them from the trials. Similarly, 85% of patients with cognitive impairment had at least one disqualifying condition.

And more than three-quarters of those with Alzheimer's disease-related dementia had several of these disqualifiers, the researchers noted.

"Clinical trials of aducanumab studied relatively healthy participants who do not reflect the majority of older adults with dementia in the U.S.," Anderson said. "As a result, Medicare should consider restricting coverage for aducanumab to patients who meet the trial eligibility criteria."

He said additional clinical trials of the high-risk groups excluded from the prior trials should be required and include rigorous study of adverse events.

The report was published Sept. 14 in the Journal of the American Medical Association.

In July, it was reported that two Congressional committees were looking into the process that led to the drug's approval and its steep cost. Although an FDA advisory committee concluded there wasn't enough evidence to support the effectiveness of Aduhelm, the FDA approved it. Three of the advisory committee members then resigned.

More information

For more on Alzheimer's disease, see the Alzheimer's Association.

SOURCE: Beth Israel Lahey Health, news release, Sept. 14, 2021




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net